Black Diamond Therapeutics logo
Black Diamond Therapeutics
BDTX | NASDAQ
Chart Builder DCF Calculator
$1.53
+$0.06 (+4.08%)
At close: Nov 16, 2026, 4:00 PM ET
$1.49
-$0.04 (-2.92%)
After-hours: Nov 16, 2026, 7:30 PM ET

Black Diamond Therapeutics Company Profile

Company profile explained

Company Profile

Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Key Executives

Name Position
Mark A. Velleca Chief Executive Officer, President & Chairman
Brent Hatzis-Schoch Chief Operating Officer & General Counsel
Elizabeth Buck Co-Founder & Chief Scientific Officer
Erika Jones Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
Melanie Morrison Chief Development Officer
Sergey Yurasov Chief Medical Officer

Latest SEC Filings

Date Type Title
Sep 21, 2026 4 Filing
Sep 21, 2026 4 Filing
Aug 05, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
Jul 27, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 08, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 29, 2026 4 Filing
Jun 29, 2026 4 Filing
Jun 29, 2026 4 Filing
Jun 29, 2026 4 Filing
View All SEC Filings ➞
Black Diamond Therapeutics
Black Diamond Therapeutics logo
Country United States
IPO Date Jan 31, 2020
Industry Biotechnology
Sector Healthcare
Employees 21
CEO Mark A. Velleca

Contact Details

245 First Street Cambridge, Massachusetts 02142 United States

Stock Details

Ticker Symbol BDTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001701541
CUSIP Number 09203E105
ISIN Number US09203E1055
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.